RxDoctor Payments Data

Howard Worman

Hepatology · New York, NYNPI 1649339912

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $110,430 of the $118,652 with a category attached, or 93.1%. Sarepta Therapeutics, Inc. accounts for 99.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $64,152 and has fallen 61.0% since, to $25,001 in 2025.

$118,652in general payments, 2019–2025

Across 66 payments — averaging $1797.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sarepta Therapeutics, Inc.$118K
  • AstraZeneca$760
  • Intra-sana Laboratories$39
$843,167in research payments, 2019–2025

Across 23 payments — averaging $36,659 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sarepta Therapeutics, Inc.$833K
  • Eiger Biopharmaceuticals, Inc.$10K

What the payments were for

  • Consulting fees$110,43093%
  • Travel & lodging$7,6806%
  • Food & beverage$5430%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$118,652 in reported general payments places this provider in the 75th percentile of 29 hepatology providers in New York.

See all hepatology providers in New York

Other hepatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →